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ERRATUM
Thearticle “Economic Evaluationof ReamedversusUnreamed IntramedullaryNailing in PatientswithClosedandOpenTibial Fractures: Results
from theStudy to Prospectively Evaluate Reamed IntramedullaryNails in PatientswithTibial Fractures (SPRINT),” byBriel et al.waspublished in
Value inHealth 2011;14:450–7. The correct author by-line is as follows: TheSPRINT Investigators. The full listing of the SPRINT Investigatorswho
took part in the collaboration of this article can be found in the Acknowledgments section of the article.
ERRATUM
The article “Economic Impact of Nonpersistence with Antidepressant Treatment in the Adult Population of Quebec: A Comparative
Cost-Effectiveness Approach,” by Béland et al (Value in Health 2011;14:492-8), was published with an incorrect Figure 1. The correct
Figure 1 is shown below.
Fig. 1 – Mean total costs and effectiveness of alternative antidepressant treatment.
